/stocks — the workspaceLOADING
All BBIOSEC filings, by type → · Earnings date & implied move · Search inside filings
BridgeBio Pharma, Inc. (BBIO) is a pharmaceutical preparations company. Piotroski F-Score 3/8. 19 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-10-28 from BBIO's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind BBIO’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from BBIO’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on BBIO plus an auto-SWOT — built from BBIO's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate BBIO using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has BBIO been issuing shares? Offering history →
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
| Apuli MaricelChief Accounting Officer | SELL | $160K | view → |
| Cook Jennifer E.Director | SELL | $13.2M | view → |
| Ellis AndreaDirector | SELL | $1.4M | view → |
| Valantine HannahDirector | SELL | $342K | view → |
| Cook Jennifer E.Director | SELL | $2.8M | view → |
| Cook Jennifer E.Director | SELL | $6.0M | view → |
| Kumar NeilChief Executive Officer | SELL | $5.4M | view → |
| Kumar NeilChief Executive Officer | SELL | $1.8M | view → |
| Viking Global (Andreas Halvorsen) | $741.0M | 2.1% of portfolio |
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.
| Gilbert CisnerosU.S. Representative · CA-39 | BUY | $1,001 - $15,000 | filed 2026-06-08 |
Only 2 of 5 tests could be computed from the filings — too few to summarise, so the individual results are shown without an overall label.
The score is passed over computable, not passed out of five. If only three tests could be run on BBIO’s filings, the score is out of three and the other two are listed with the reason they were skipped. Scoring a skipped test as a failure would punish a company for how its industry reports, and scoring it as a pass would flatter one.
Labels come from that ratio:
Below three computable tests we publish no label at all and show the individual results instead. A summary drawn from one or two tests is not a summary.
Free cash flow coverage carries the most weight in practice, because dividends are paid in cash and free cash flow is the cash actually available to pay them. The earnings payout ratio is the better-known test but the weaker one — earnings are an accounting figure, dividends are not. Where the two disagree, believe the cash.
Why tests get skipped.A REIT gets no earnings payout ratio: GAAP depreciation on appreciating property understates a REIT’s distributable earnings, which is exactly why the industry reports FFO and why REITs are required to distribute most of their taxable income. Banks and insurers get no leverage test, because deposits are debt and structurally high leverage is what a balance-sheet business is, not a warning sign.
The biggest limitation, stated plainly. The coverage tests read a single fiscal year, and one year of cash flow is far more volatile than a dividend record. A legal settlement, a tax payment or an acquisition can sink coverage in a year that says nothing about the dividend. Where a weak year contradicts a long unbroken record, we say so above rather than letting the harsher number stand alone — but you should still check what happened in that specific year.
The streak is the weakest test here, and it is deliberately listed last. Every dividend that was ever cut had an unbroken streak right up until the year it was cut. A freeze does not break the run — a company that holds its dividend flat through a bad year has not cut it — so raises are counted separately, and a long flat run cannot pass itself off as dividend growth.
Every figure above is from BBIO’s own SEC filings and the arithmetic is stated on this page. This describes what the filings show about the dividend’s coverage — it is not a prediction that the dividend will or will not be cut, not a recommendation, and not investment advice. A covered dividend can still be cut, and a strained one can still be maintained for years. Educational information only.
Projected from BBIO's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentBBIO files or announces.
BBIO has sold off after 5 of its last 8 earnings reports.
Each figure is one earnings reaction — how much BBIO moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Earnings reactions have been mild.
BBIO has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+6.9% and -6.2%).
A more typical earnings reaction has been approximately ±1.9%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-10 | -0.9% |
| 2026-05-07 | -1.0% |
| 2026-02-24 | -2.0% |
| 2026-01-12 | +2.4% |
| 2025-10-29 | -1.8% |
| 2025-08-05 | -6.2% |
| 2025-04-29 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| +6.9% |
| 2025-02-20 | +1.5% |